Navamedic expands product portfolio
Navamedic ASA (OSE: NAVA) today announced that the Company has included the antithrombotic drug Arixtra in its product portfolio. The product has a EUR 1 million sales potential in the Nordic markets.
Arixtra is primarily used by hospitals to prevent blood from clotting during and after heart and coronary artery surgery.
Navamedic assumes distribution of Arixtra in the Nordic markets, following the Company's expanded co-operation with pharmaceutical manufacturer Aspen of South Africa. Navamedic announced the expansion of the partnership in May 2014, indicating additional annual sales of MNOK 40. Sales income from Arixtra was not included in this estimate.
For further information, please call Håkan Josephsson, acting CEO, telephone +46 706 742 533 or Bjørn Lindholt, CFO, telephone +47 9300 6601.
Navamedic ASA is a Norwegian pharmaceutical products company, marketing and distributing more than 120 products in the Nordic and Benelux markets. The Company operates three business areas; Pharma Products, Medical Nutrition and Consumer Care based on its relationship with a number of pharmaceutical product manufacturers. Navamedic is listed on the Oslo Stock Exchange (ticker: NAVA).